Glicentin inhibits gastric acid secretion in the rat

Kirkegaard, Preben; Moody, A. J.; Holst, Jens J.; Loud, F. B.; Olsen, Peter Skov; Christiansen, John

doi:10.1038/297156a0

Cited by 85 publications

(44 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent study using high pressure liquid chromatography for the determination of oxyntomodulin in rat plasma, Kervran et al [19] found that oxyntomodulin was the predominating circulating enteroglucagon and that its concentration increased markedly in response to a meal. Furthermore, glicentin has been shown to inhibit gastric acid secretion in rats [20], and may exert its activity in a manner which is homologous to that of oxyntomodulin. Possibly, therefore, the concentrations obtained in this study may represent-as for the effect on gastric acid secretion-a physiologically relevant imitation of the total secretion of enteroglucagons in response to a meal.…”

Section: Discussionmentioning

confidence: 99%

Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man

Schjoldager

Baldissera²,

Mortensen

et al. 1988

Eur J Clin Investigation

Self Cite

124

View full text Add to dashboard Cite

Abstract. Synthetic oxyntomodulin, a predicted product of the glucagon gene, which is produced in the human lower intestinal mucosa, was infused in doses of 100 and 400 ng kg-' h-' into six volunteers to study its pharmacokinetics and effects on pentagastrinstimulated gastric acid secretion (100 ng kg-' h-I). The concentration of oxyntomodulin in plasma measured with a cross-reacting glucagon assay increased from 37+5 to 106+ 17and 301 k40pmol I-', respectively. The metabolic clearance rate was 5.2k0.7 ml kg-' min-' and the half-life in plasma was 12 & 1 min. Oxyntomodulin reduced the pentagastrin-stimulated acid secretion by 20 f 9% during the low-rate infusion ( P < 0.05) and by 76 f 10% during the high-rate infusion (P < 0.05). In accordance with the homology with glucagon, there was a small, significant rise in plasma concentrations of insulin and insulin C-peptide during oxyntomodulin infusion. Oxyntomodulin may therefore be included among the potential incretins and enterogastrones in man.

show abstract

Section: Discussionmentioning

confidence: 99%

Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man

Schjoldager

Baldissera²,

Mortensen

et al. 1988

Eur J Clin Investigation

Self Cite

124

View full text Add to dashboard Cite

show abstract

“…Recently, GLP-2 has also been found to be an inhibitor of food intake in the rat (14). Glicentin acts within peripheral tissues, with its roles including the inhibition of gastric acid secretion in the rat (15). No effect of glicentin in the CNS has been reported to date.…”

Section: P Reproglucagon Is Cleaved In a Tissue-specificmentioning

confidence: 99%

Oxyntomodulin Inhibits Food Intake in the Rat

et al. 2001

View full text Add to dashboard Cite

Oxyntomodulin is derived from proglucagon processing in the intestine and the central nervous system. To date, no role in the central nervous system has been demonstrated. We report here that oxyntomodulin inhibits refeeding when injected intracerebroventricularly and into the hypothalamic paraventricular nucleus of 24-h fasted rats [intracerebroventricularly and into the paraventricular nucleus, 1 h, oxyntomodulin (1 nmol), 3.1 ؎ 0.5 g; saline, 6.2 ؎ 0.4 g; P < 0.005]. In addition, oxyntomodulin inhibits food intake in nonfasted rats injected at the onset of the dark phase (intracerebroventricularly, 1 h: oxyntomodulin, 3 nmol, 1.1 ؎ 0.19 g vs. saline, 2.3 ؎ 0.2 g; P < 0.05). This effect of oxyntomodulin on feeding is of a similar time course and magnitude as that of an equimolar dose of glucagon-like peptide-1. Other proglucagonderived products investigated [glucagon, glicentin (intracerebroventricularly, 3 nmol; into the paraventricular nucleus, 1 nmol), and spacer peptide-1 (intracerebroventricularly and into the paraventricular nucleus, 3 nmol)] had no effect on feeding at any time point examined. The anorectic effect of oxyntomodulin (intracerebroventricularly, 3 nmol; into the paraventricular nucleus, 1 nmol) was blocked when it was coadministered with the glucagon-like peptide-1 receptor antagonist, exendin-(9 -39) (intracerebroventricularly, 100 nmol; into the paraventricular nucleus, 10 nmol). However, oxyntomodulin has a lower affinity for the glucagon-like peptide-1 receptor compared with glucagon-like peptide-1 (IC 50 : oxyntomodulin, 8.2 nM; glucagon-like peptide-1, 0.16 nM). One explanation for this is that there might be an oxyntomodulin receptor to which exendin-(9 -39) can also bind and act as an antagonist. (Endocrinology 142: 4244 -4250, 2001)

show abstract

“…The secretion of glicentin and oxyntomodulin by the intestinal L cells is stimulated in parallel with that of GLP1 and GLP2 by the luminal presence of digested nutrients (including carbohydrates, proteins and fat) (9) depending on the size of the meal. The possible biological effects of glicentin are unclear, although an effect on gastric acid secretion has been reported (17). Oxyntomodulin, on the other hand, has been shown in animal and human intervention studies to reduce food intake, with a resulting weight reduction (18).…”

Section: Introductionmentioning

confidence: 99%

Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans

Bąk¹,

Albrechtsen

Pedersen

et al. 2014

European Journal of Endocrinology

124

112

View full text Add to dashboard Cite

Aim: To determine the specificity and sensitivity of assays carried out using commercially available kits for glucagon and/or oxyntomodulin measurements. Methods: Ten different assay kits used for the measurement of either glucagon or oxyntomodulin concentrations were obtained. Solutions of synthetic glucagon (proglucagon (PG) residues 33-61), oxyntomodulin (PG residues 33-69) and glicentin (PG residues 1-69) were prepared and peptide concentrations were verified by quantitative amino acid analysis and a processing-independent in-house RIA. Peptides were added to the matrix (assay buffer) supplied with the kits (concentration range: 1.25-300 pmol/l) and to human plasma and recoveries were determined. Assays yielding meaningful results were analysed for precision and sensitivity by repeated analysis and ability to discriminate low concentrations.

show abstract

Glicentin inhibits gastric acid secretion in the rat

Cited by 85 publications

References 9 publications

Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man

Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man

Oxyntomodulin Inhibits Food Intake in the Rat

Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans

Contact Info

Product

Resources

About